← All trials
NCT05693688
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2017
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2024
- First posted
- Jan 23, 2023
- Last posted
- Feb 1, 2023
- Enrollment
- 760
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AmsterdamLead sponsor
- University of AmsterdamReponsible party - principal investigator
- Amphia Hospital Breda, the NetherlandsCollaborator
- Deventer ZiekenhuisCollaborator
- Utrecht UniversityCollaborator
- Erasmus University RotterdamCollaborator
- FlevoziekenhuisCollaborator
- Franciscus GasthuisCollaborator
- Gelre HospitalsCollaborator
- Medical Center HaaglandenCollaborator
- Isala Clinics, Zwolle, The NetherlandsCollaborator
- Leiden UniversityCollaborator
- Maastricht UniversityCollaborator
- University of GroningenCollaborator
- Maastricht UniversityCollaborator
- Medical Center LeeuwardenCollaborator
- Medisch Spectrum TwenteCollaborator
- National Maternity Hospital, IrelandCollaborator
- University of NottinghamCollaborator
- OLVG hospital, AmsterdamCollaborator
- Radboud UniversityCollaborator
- Rijnstate HospitalCollaborator
- Spaarne GasthuisCollaborator
- St. Antonius Hospital, NieuwegeinCollaborator
- Tergooi HospitalCollaborator
- Utrecht UniversityCollaborator
- University of GroningenCollaborator
- University of TwenteCollaborator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- Zuyderland Medisch CentrumCollaborator
- University of AmsterdamSponsor investigator
- Groene Hart ZiekenhuisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.